Our commitment to quality: batch by batch

Avextra offers high-quality cannabis-based medicines. Our strength lies within our cultivation in Portugal and the combination of traditional and high-tech extraction methods in Germany. Discover more insights from our CMO David Reckeweg-Lecompte by watching this video.

Podcasts

Neil Smith featured on Planted with Sara Payan.

Sara discusses the European cannabis landscape and new movement in R&D with Neil Smith, COO of German bio-pharmaceutical company Avextra.

Press Releases

Please find the latest press releases from Avextra here.

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

In Folge einer Krebsbehandlung leiden 60-80% aller Onkologiepatientinnen und -patienten an  Chemotherapie-induzierten neuropathischen Schmerzen (CINP) in Form von bleibenden Schmerzen und Taubheitssymptomen – eine schwerwiegende Beeinträchtigung ihrer Lebensqualität. Die Deutsche…

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten klinischen Studie für Onkologiepatient:innen. Zum…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to…

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

Strategic partnership deepens Research & Development of medicinal cannabis in areas such as clinical trials, development of medical devices, and extraction methodologies.  Avextra will actively participate in the supervision of…

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…

PRESS CONTaCT

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

EN